Latest Contract Research Organisations News

Page 2 of 6
TrivarX has locked in investigational product supply critical for starting its Phase 1 clinical trial of the Stabl-Im MRI imaging platform, targeting a 2026 trial commencement.
Ada Torres
Ada Torres
16 July 2026
INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.
Ada Torres
Ada Torres
14 July 2026
INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.
Ada Torres
Ada Torres
13 July 2026
Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.
Ada Torres
Ada Torres
7 July 2026
Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.
Ada Torres
Ada Torres
10 June 2026
Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.
Ada Torres
Ada Torres
28 May 2026
TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.
Ada Torres
Ada Torres
22 May 2026
Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.
Ada Torres
Ada Torres
20 May 2026
Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.
Ada Torres
Ada Torres
5 May 2026
TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.
Ada Torres
Ada Torres
30 Apr 2026
Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.
Ada Torres
Ada Torres
30 Apr 2026
Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.
Ada Torres
Ada Torres
29 Apr 2026

Browse the archive

Full archive